Localization-Related (Focal) (Partial) Idiopathic Epilepsy and Epileptic Syndromes With Seizures of Localized Onset, MCP-2: Monocyte Chemo-attractant Protein-2, TRAIL: Tumor Necrosis Factor Related Apoptosis Inducing Ligand MCP-2
Conditions
Brief summary
1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. Possible role to predict the prognosis of patients with epileptic seizure.
Detailed description
Epilepsy is one of the most prevalent neurological disorders characterized by frequent somatic and psychiatric co-morbidities(1). Accurate diagnosis of epilepsy is challenging because clinicians rarely observe the actual clinical seizure outside of the hospital. Furthermore, psychogenic nonepileptic seizures (PNES) can mimic epileptic seizures (ES), leading to erroneous diagnosis and inappropriate treatments. A critical gap in the diagnostic assessment of seizures is a blood test that can distinguish ES from PNES (2). Both diagnoses were confirmed by the gold standard diagnostic method video/electroencephalogram (EEG) monitoring (3). Taking all in to account, the notion that neuro-inflammation is the key pathology behind focal epileptic seizure initiation and maintenance and the dynamic and adaptative process of neuro -inflammation is associated with blood-brain-barrier disruption and glial activation is no longer a surprise (4). Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates immune responses via apoptosis, with lower levels associated with severe infection, including sepsis (5). Monocyte chemoattractant protein-2 (MCP-2) has been well recognized to participate in immune regulation via binding to chemokine receptors and activation chemotaxis in lymphocytes T, natural killer (NK) cells, and monocytes therefore contributing to the pathogenesis of monocyte-dependent tissue injury (6). Hence, MCP-2 overexpression could result in an increased immune response. Further, since increased levels of MCP-2 have been observed in patients with Alzheimer's disease, this may further support the existence of the biodirections relationship between neurodegeneration and seizures/epilepsy (7).
Interventions
OTHERMeasuring inflammatory serum biomarkers
Measuring inflammatory serum biomarkers
Sponsors
Esraa Mostafa Ahmed Abdel Aal
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients diagnosed as epileptic seizure are aged \>12 years patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years Normal healthy control for comparison. Heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw
Exclusion criteria
* Neurological criteria: Other CNS disorders including Parkinson's disease, amyotrophic lateral sclerosis ,cerebrovascular stroke, Psychiatric disorders {major depression disorder , generalized anxiety, mania and other psychiatric diseases). Others: Tumors and cardiovascular
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1- Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure | in first 24 hours of seizure | Measurement of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. |
| 2- Possible role to predict the prognosis of patients with epileptic seizure. | in first 24 hours of seizure | Differentiation between epileptic seizure and psychogenic non-epileptic seizure help in diagnosis and predict prognosis of seizure |
Contacts
Primary ContactEsraa Mostafa, Master
Backup ContactYousra Mohamed, Doctora
Outcome results
None listed